ストックスクリーナーアプリを入手
16.16
1.04%
-0.17
前日終値:
$16.33
開ける：
$16.05
24時間の取引高:
3.16M
Relative Volume:
1.14
時価総額：
$51.05B
収益：
$29.63B
当期純損益:
$260.53M
株価収益率:
205.08
EPS:
0.0788
ネットキャッシュフロー:
$5.51B
1週間 パフォーマンス:
-0.92%
1か月 パフォーマンス:
+11.22%
6か月 パフォーマンス:
+9.78%
1年 パフォーマンス:
+23.83%
1日の値動き範囲:
$16.05
$16.20
1週間の範囲:
$15.87
$16.48
52週間の値動き範囲:
$12.80
$16.48
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
TAK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
16.16 | 51.59B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
ZTS
Zoetis Inc
|
124.65 | 55.21B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
9.83 | 43.51B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.76 | 37.11B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
464.93 | 20.32B | 3.08B | 1.24B | 1.07B | 25.61 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 再開されました | Morgan Stanley | Overweight |
| 2025-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Takeda Pharmaceutical ADR Sees IBD RS Rating Climb To 76 - Investor's Business Daily
Book value per share of Takeda Pharmaceutical Co. Ltd. Sponsored ADR – GETTEX:TKDA - TradingView — Track All Markets
The Truth About Takeda Pharmaceutical Co Ltd: Is This Pharma Giant a Hidden Power Play for Your Port - AD HOC NEWS
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
Ethic Inc. Buys 43,295 Shares of Takeda Pharmaceutical Co. $TAK - Defense World
Takeda Pharmaceutical (NYSE:TAK) Strengthens Position in Healthcare - Kalkine Media
Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd ADR Stock Price Today | NYSE: TAK Live - Investing.com
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛
Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria
CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com
BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com
CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se
INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com
INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo
Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com
5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool
Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
0.50%
0.61%
大文字化:
|
ボリューム (24 時間):